Alerta

一种响应型抗原捕获纳米平台及其制备方法和应用

Resumen de: CN120754061A

本发明涉及肿瘤免疫治疗技术领域。本发明提供了一种响应型抗原捕获纳米平台及其制备方法和应用。本发明的产品通过静脉注射等全身给药方式应用；能特异性响应肿瘤微环境中的过氧亚硝酸盐，实现肿瘤部位的精准激活；可通过高效共价捕获肿瘤相关抗原，将抗原递送至抗原呈递细胞中，以此增强抗肿瘤免疫应答；结合光动力治疗能显著抑制肿瘤生长。

一种靶向阻断交感神经与肿瘤串扰的载药杂化纳米囊泡及其制备方法

Resumen de: CN120754062A

本申请属于抗肿瘤药物制备技术领域，更具体地，涉及一种靶向阻断交感神经与肿瘤串扰的载药杂化纳米囊泡及其制备方法。本申请提供的载药杂化纳米囊泡，包括M1型巨噬细胞来源纳米囊泡与酸敏感脂质体水合形成的杂化纳米囊泡，以及该杂化纳米囊泡包裹的能够抑制交感神经与肿瘤串扰的药物。该载药杂化纳米囊泡能够有效靶向肿瘤组织，降解肿瘤胞外致密基质，并能够响应肿瘤微酸环境释放药物，实现药物在肿瘤部位的高效富集以及深度渗透，有效阻断慢性应激条件下交感神经与肿瘤之间的互作，抑制肿瘤中的神经浸润与神经递质分泌，改善肿瘤免疫微环境，从而有效抑制肿瘤生长。此外，上述载药杂化纳米囊泡的生物安全性高，具备良好的临床应用前景。

甲状腺素转运蛋白基因的碱基编辑

Resumen de: US2025312491A1

Provided herein are compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed by the aggregation of misfolded transthyretin (TTR) proteins. Such conditions include, but are not limited to, polyneuropathy due to hereditary transthyretin amyloidosis (hATTR-PN) and hereditary cardiomyopathy due to transthyretin amyloidosis (hATTR-CM), both associated with autosomal dominant mutations of the TTR gene, and an age-related cardiomyopathy associated with wild-type TTR proteins (ATTRwt), also known as senile cardiac amyloidosis.

一种二烃基咪唑仿生型脂质化合物及其制备方法和应用

Resumen de: CN120757505A

本发明涉及一种二烃基咪唑仿生型脂质化合物及其制备方法和应用，二烃基咪唑仿生型脂质化合物结构仿天然磷脂设计，在咪唑的4位与5位上修饰不少于10个碳原子的烃基，且在2位上修饰不同烷基链长的伯胺；二烃基咪唑仿生型脂质化合物与治疗性药物以及其他辅料混合，能够制备得到治疗性药物被装载在内的脂质纳米颗粒，能够作为药物递送系统用于脑靶向药物的制备。二烃基咪唑仿生型脂质具备动态调控血脑屏障的功能，可以实现血脑屏障的可逆开放；形成的载药脂质组合物能够穿越血脑屏障并较好的实现所装载治疗性药物的脑靶向递送；由二烃基咪唑仿生型脂质组成的载药脂质组合物属于新一代仿生纳米药物载体，为实现不同种类药物的脑靶向递送提供了新策略。

解吉那保石油醚提取物在治疗肝癌中的应用

Resumen de: CN120754155A

本发明公开解吉那保石油醚提取物在治疗肝癌中的应用，属于肝癌防治领域；本发明提出了解吉那保石油醚提取物(GC‑PE)在治疗或者预防肝癌中的应用，揭示了GC‑PE治疗可显著降低人肝癌细胞Hep‑G2的细胞活力，其作用机制可能与促进Hep‑G2细胞周期阻滞、凋亡有关。将GC‑PE与阳性药紫杉醇(PTX)进行比较，其抑制肝癌细胞增殖和侵袭的效果更加显著。网络药理学分析结果显示，解吉那保可能通过PI3K/AKT信号通路促进肝癌细胞周期阻滞、细胞凋亡，并通过分子对接预测解吉那保中的活性成分与PI3K/AKT信号通路中的关键靶蛋白PIK3CA结合，发挥其抗肿瘤的作用。

一种核酸递送载体及其制备方法和应用

Resumen de: CN120754262A

本发明公开了一种核酸递送载体及其制备方法和应用，属于药物递送载体技术领域。本发明提供的核酸递送载体基于LNP结构，保留关键脂质或类脂质不变，通过改变LNP的表面组成，可以有效减少LNP在肝脏中的积累，实现有效的mRNA原位传递和蛋白质表达；进而实现大幅改善LNP器官毒性、减轻mRNA药物副作用、提高mRNA药物耐受性的效果；通过促进载体的原位摄取量、增强内涵体逃逸两个方面实现原位靶向和核酸的高表达；通过对各组分和参数进行优化或添加活性脂质，均可以增强制备的核酸递送载体的原位表达水平和稳定性；在使用后，对施用部分进行超声，也可以促进核酸配送载体的原位表达水平。

一种卡马西平的生产工艺及负载分散剂

Resumen de: CN120754274A

本申请涉及药物制剂的技术领域，具体涉及一种卡马西平的生产工艺及负载分散剂。本申请首先将β‑环糊精接枝于壳聚糖分子链上制得负载分散剂，然后在酸性条件下，负载分散剂中壳聚糖分子中的氨基被质子化后与羧甲基纤维素钠中的羧酸根负离子相互作用，形成纳米粒子，最后再负载卡马西平药物。通过上述生产工艺获得的纳米粒子含有疏水空腔，且具有较大的比表面积，因此载药量和包封率较高，累积释放率也较高，说明该纳米粒子载药后具有良好的溶出性能。另外，采用甲氧基聚乙二醇进一步改性后，在一定程度上可以提高载药纳米粒子的载药量和包封率，从而进一步提升其溶出性能。

一种靶向免疫细胞的纳米载药系统

Resumen de: CN120754063A

本发明公开了一种靶向免疫细胞的纳米载药系统。包括由聚乳酸‑羟基乙酸共聚物构成的核心纳米颗粒，用于包封治疗药物；包覆于核心表面的聚乙二醇功能层，延长血液循环时间；共价连接于聚乙二醇层的靶向配体，该配体为特异性识别免疫细胞表面受体的高亲和力配体，包括抗DEC205单链抗体片段、甘露糖或抗CD3抗体片段。创新点在于靶向配体对树突状细胞、巨噬细胞或T细胞表面特定受体的结合亲和力显著高于常规配体，且通过聚乳酸‑羟基乙酸共聚物‑聚乙二醇‑配体的协同结构实现高效胞内递送。技术效果包括体外对目标免疫细胞的摄取效率大幅提升，荷瘤小鼠肿瘤组织药物富集度较非靶向载体成倍提高，并显著增强抗原提呈和T细胞活化能力。

一种聚乙二醇化顺铂化合物及其制备方法和应用

Resumen de: CN120757770A

本申请涉及一种聚乙二醇化顺铂化合物及其制备方法和应用，属于药物载体技术领域。本申请通过聚乙二醇与顺铂的共价偶联得到聚乙二醇化顺铂化合物。本申请提供了新型聚乙二醇化顺铂化合物及其制备方法、包含所述聚乙二醇化顺铂化合物以及含有该化合物的药物组合物及其制剂，尤其是含有该聚乙二醇化顺铂化合物的核酸药物组合物及其制剂，核酸药物组合物制剂能将核酸类药物递送至细胞内，提高核酸类药物的转运率，降低了毒性，从而提高核酸类药物的治疗效果。

纳米载药系统及其制备方法和应用

Resumen de: CN120754060A

本申请公开了一种纳米载药系统及其制备方法和应用，纳米载药系统包括纳米颗粒、血小板膜、组织型纤溶酶原激活剂和凝血酶特异性适配体，血小板膜至少部分包覆纳米颗粒，组织型纤溶酶原激活剂和凝血酶特异性适配体连接于血小板膜。本申请的纳米载药系统，具有良好的靶向性、快速溶栓作用，且具有局部抗凝作用，有利于避免继发凝血和再栓塞风险。

一种用于皮肤疾病修复与抗衰老的干细胞外泌体组合物及其制备方法

Resumen de: CN120754131A

本发明属于技术领域，公开了一种用于皮肤疾病修复与抗衰老的干细胞外泌体组合物及其制备方法，产品采用MSC和ADSC外泌体的联合应用，在促进皮肤修复和抗衰老方面具有互补作用，MSC外泌体增强皮肤再生，而ADSC外泌体具有更好的抗炎和抗衰老作用，纳米胶囊载体不仅能提升外泌体的稳定性，还能优化其皮肤渗透性，延长外泌体的作用时间，通过加入皮肤屏障修复成分（如角鲨烯和神经酰胺），使得外泌体在修复皮肤的同时，还能够增强皮肤自我修复能力，改善皮肤屏障功能。

一种碱性氨基酸修饰的3S-PCL及其制备方法和用途

Resumen de: CN120757763A

本发明公开了一种碱性氨基酸修饰的3S‑PCL及其制备方法和用途，涉及生物医药技术领域。该碱性氨基酸修饰的3S‑PCL的结构式如下：；其中，R为碱性氨基酸；m、m1和m2均为正整数，且m、m1、m2≥1。本发明设计并合成了一种碱性氨基酸修饰的三臂聚己内酯（3S‑PCL）材料，其具有良好的生物相容性，可以替代阳离子脂质体用于脂质纳米粒核酸递送。该碱性氨基酸修饰的3S‑PCL材料制备方法简单快速，特别适合于工业化生产。以该碱性氨基酸修饰的3S‑PCL材料作为基因载体制备的脂质纳米粒可以实现对核酸药物的高效递送。

一种改性普鲁士蓝纳米粒子及其制备方法和应用

Resumen de: CN120754245A

本发明涉及肿瘤纳米医学技术领域，公开了一种改性普鲁士蓝纳米粒子及其制备方法和应用。所述改性普鲁士蓝纳米粒子为表面依次经鞣酸包覆和锰离子修饰的铪掺杂普鲁士蓝纳米颗粒，该改性普鲁士蓝纳米粒子，通过铪增强放疗增敏、普鲁士蓝介导光热治疗以及Mn2+激活STING免疫通路的三重机制，应用于制备骨肉瘤放疗药物时，能够显著提升抗肿瘤效果，体外试验验证其可通过ROS爆发、DNA损伤和凋亡三重机制根除肿瘤细胞，体内试验显示其可完全抑制原位骨肉瘤并消除肺转移，疗效显著优于单一疗法；通过鞣酸包覆赋予负电荷，实现静脉给药后高效肿瘤靶向，同时具备优异的生物相容性。

一种负载镇痛药物的卵磷脂壳聚糖纳米粒凝胶及其制备方法和应用

Resumen de: CN120754028A

本发明提供了一种负载镇痛药物的卵磷脂壳聚糖纳米粒凝胶及其制备方法和应用，属于医用生物材料技术领域。本发明通过将镇痛药物包载在卵磷脂壳聚糖纳米粒中，能够使镇痛药物缓慢释放，延长药物镇痛时间。本发明将包载镇痛药物的卵磷脂壳聚糖纳米粒分散在凝胶基质中，通过对凝胶基质的选择，使包载镇痛药物的卵磷脂壳聚糖纳米粒可以较快穿透皮肤角质层，使负载镇痛药物的卵磷脂壳聚糖纳米粒凝胶可以发挥速效透皮和缓释相药物相结合的作用，提高生物利用度，延长镇痛药物作用时间，发挥长时间镇痛的效果。

用于IBD治疗的单原子纳米酶递药系统及其制备方法和应用

Resumen de: CN120754064A

本发明涉及纳米材料技术领域，具体涉及一种用于IBD治疗的单原子纳米酶递药系统及其制备方法和应用。本发明提供的单原子纳米酶递送系统，包括铁掺杂单原子纳米酶Fe‑SA、姜黄素Cur和透明质酸接枝多巴胺HAD；所述Fe‑SA与Cur通过配位作用形成Fe‑SA/Cur复合物，所述HAD包覆于所述Fe‑SA/Cur复合物表面。本发明中，所述铁掺杂单原子纳米酶Fe‑SA中Fe原子以Fe‑N4共掺杂形式分布于Fe‑SA的分级碳基基质中，具有高效的SOD和CAT纳米酶活性，能实现抗氧化自级联纳米酶反应，有效清除活性氧，改善病理环境。本发明利用铁掺杂单原子纳米酶和姜黄素构建配位复合物Fe‑SA/Cur，既增加了抗炎效果，又有效改善了姜黄素水溶性差的特点。本发明在配位复合物Fe‑SA/Cur外层负载HAD构建可口服的单原子抗氧化级联纳米酶系统，利用HAD显著的稳定性和负电荷实现了高耐酸性和靶向递送能力，有效实现了口服给药。体内外实验表明本发明提供的单原子纳米酶递送系统可有效清除肠道自由基，改善肠道环境，降低炎症因子表达，促进受损组织恢复，有效治疗结肠炎。本发明为炎症性肠病的生物医学研究和药物开发提供了新的思路和方法。

POLYMER MICROSPHERES LOADED WITH METAL NANOPARTICLES, PREPARATION METHOD THEREFOR, AND USE THEREOF

Resumen de: WO2025208819A1

The present invention relates to polymer microspheres loaded with metal nanoparticles, a preparation method therefor, and use thereof. The present invention pertains to the technical field of tumor embolization therapy. The polymer microspheres loaded with metal nanoparticles are characterized by comprising a polymer microsphere framework and metal nanoparticles distributed in the polymer microsphere framework; the metal nanoparticles are manganese nanoparticles or iron nanoparticles; the particle size of the metal nanoparticles is 600 nm-1000 nm. The particle size of the polymer microspheres meets the requirements of embolization therapy. The polymer microspheres can embolize local blood vessels, achieving an embolization therapy effect. Due to the addition of the metal nanoparticles, the microspheres have a higher rigidity and a better embolization effect than traditional polymer microspheres. The preparation yield of the polymer microspheres loaded with metal nanoparticles of the present invention is significantly higher (2-3 times) than the yield of polymer microspheres loaded with active metal microparticles such as magnesium microparticles, the production efficiency and the production safety are higher, and the production cost is lower.

LIPID NANOPARTICLES FOR INDUCING AN IMMUNOLOGICAL RESPONSE

Resumen de: WO2025210520A1

The present disclosure provides lipid nanoparticles that are particularly beneficial in inducing an immune response in a subject, particularly by stimulating production of antibodies by the subject. The lipid nanoparticles can include one or more of a low conjugated lipid concentration, a neutral phospholipid, and a concentration of an ionizable lipid and/or sterol that satisfy certain thresholds dependent on the conjugated lipid concentration. The disclosure also provides vaccines, other pharmaceutical compositions, and methods including the provided lipid nanoparticles.

LIPID NANOPARTICLES FOR THE TREATMENT OF VASCULAR DISEASES

Resumen de: WO2025213135A1

Described herein are lipid nanoparticle (LNP) formulations with demonstrated tropism towards smooth muscle cells. Also described herein are LNPs conjugated with peptides that can target tissue or cell surface receptors. The formulations of the disclosure include amounts of DOTAP, an ionizable lipid, amounts of a neutral lipid; amounts of cholesterol; and amounts of one or more PEG-lipids with preferential tropism towards vascular smooth muscle cells (vSMCs). Also described herein are peptides that target receptors highly expressed on the surface of vSMCs (1L-6R, CD63 and GAL-3) or that target proteins in the extracellular matrix adjacent to vSMCs (Col-IV) increasing the uptake into these cells.

SELF-ASSEMBLED MULTILAYERED SUPRAPARTICLES

Resumen de: WO2025212420A1

A supraparticle includes and can consist of, ultrasmall Au nanoparticles, a stabilizing matrix, and a lipidoid. The supraparticle can advantageously include a labile molecule payload. A method is disclosed to self-assemble the components into ordered multi-unit structures. The method provides a self-limiting assembly process that results in finite-size supraparticles that can store and transport sensitive labile molecule payloads (for example, labile RNAs) and release them selectively upon exposure to biochemical-stimuli within cells when introduced into cells.

VACCINE TARGETING TO MUCOSAL LYMPHOID TISSUES IN THE GASTROINTESTINAL TRACT

Resumen de: WO2025212705A1

Viruses, bacteria, and parasites frequently cause infections in the gastrointestinal (GI) tract, but traditional vaccination strategies typically elicit little or no mucosal antibody responses. Disclosed herein is a vaccine comprising a nanoemulsion and an immunogen non-covalently conjugated to the surface of the nanoemulsion by an amphiphilic linker, wherein the vaccine is suitable for inducing a mucosal antibody response in the gastrointestinal tract. Also disclosed are methods of using the vaccine to immunize a subject by intraperitoneal administration of an effective amount of the vaccine, alone or with an adjuvant.

MYCOBACTERIOPHAGE FUNCTIONALIZED MAGNETIC NANOCRYSTAL CLUSTERS FOR HIGHLY SENSITIVE DETECTION OF TUBERCULOSIS AND NON-TUBERCULOSIS MYCOBACTERIUM (NTM) RELATED INFECTION

Resumen de: WO2025212695A1

A rapid and cost-effective bacilli enrichment technology is provided that combines magnetic nanotechnologies with bacteriophage. The bacteriophage provides recognition functionality, while the magnetic nanocrystal clusters have excellent separation efficiency. Using portable and inexpensive devices, one can achieve rapid, point-of-care detection of tuberculosis, Non-Tuberculosis Mycobacterium (NTM) and urinary tract infection (UTI) in clinically relevant matrices, including sputum, urine, and blood, with a detection limit of 500 cfu/mL for BCG within 35 min. Excellent potential for clinical tuberculosis diagnostics in resource-limited settings is demonstrated.

LIPID NANOPARTICLES FOR AEROSOL DELIVERY OF BASE EDITORS

Resumen de: WO2025212607A1

The present disclosure relates to pharmaceutical compositions for editing genes that can be administered through inhalation, such as via nebulization. In particular, these compositions contain β-sitosterol instead of other sterols or steroids. These compositions may show improved gene editing performance with fewer editing errors and/or improved aerosolization compared to lipid nanoparticles with cholesterol.

DELIVERY OF AURORA KINASE INHIBITORS USING NANO-SCALE DRUG DELIVERY PLATFORMS BY COVALENT CONJUGATION

Resumen de: WO2025212557A1

Described herein is a conjugate having the formula of: A(L-I)x; wherein: A is a targeting moiety; L is a covalent linker; I is an Aurora kinase inhibitor; and x is a number of Aurora kinase inhibitors per targeting moiety, and can be an integer selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and fractional integers in between, and their use in treating and/or imaging a cancer or tumor or inflammation. The targeting moiety can include a targeting antibody, a fragment of a targeting antibody, an antibody-like structure, a nanoparticle drug delivery platform, a target-specific small molecule, a macromolecule, a peptide, and a peptide fragment.

TARGETED AND DEGRADER-ENCAPSULATED NANOGELS FOR PROTEIN DEGRADATION, AND COMPOSITIONS AND METHODS THEREOF

Resumen de: WO2025212287A1

The invention provides novel antibody-nanogel conjugates with encapsulated protein degraders and related methods for controlled and targeted delivery of degrader molecules as therapeutic agents.

LIPID NANOPARTICLES COMPRISING GINSENOSIDE OR DERIVATIVE THEREOF, AND USE THEREOF

Nº publicación: WO2025211732A1 09/10/2025

Solicitante:

GENOMICTREE INC [KR]
(\uC8FC)\uC9C0\uB178\uBBF9\uD2B8\uB9AC